Viking Therapeutics (VKTX) Accounts Payables (2014 - 2026)
Viking Therapeutics (VKTX) posted Accounts Payables of $69.0 million for Q2 2026, up 2.72% sequentially from $67.2 million in Q1 2026, and up 1156.13% YoY from $5.5 million in Q2 2025.
Viking Therapeutics (VKTX) Accounts Payables (2014 - 2026) Analysis & Trends
Viking Therapeutics has reported Accounts Payables for 13 years, with the latest figure at $69.0 million in Q2 2026.
- Quarterly Accounts Payables rose 1156.13% year-over-year to $69.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $69.0 million (up 1156.13% YoY) and the FY2025 annual result came in at $53.3 million, up 442.66% from the prior year.
- Accounts Payables grew to $69.0 million in Q2 2026 per VKTX's latest filing, from $67.2 million in the prior quarter.
- Over five years, Accounts Payables peaked at $69.0 million in Q2 2026 and troughed at $254000.0 in Q3 2024.
- A 5-year average of $15.4 million and a median of $5.9 million in 2022 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables plunged 95.55% in 2024, then jumped 1637.4% in 2025.
- Over 5 years, Accounts Payables stood at $8.5 million in 2022, then declined by 11.92% to $7.5 million in 2023, then surged by 30.63% to $9.8 million in 2024, then surged by 442.66% to $53.3 million in 2025, then rose by 29.6% to $69.0 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $69.0 million, $67.2 million, and $53.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Viking Therapeutics | 3.87 Bn | 3.87 Bn | - | 69.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 69.01 Mn |
| Mar 31, 2026 | 67.18 Mn |
| Dec 31, 2025 | 53.25 Mn |
| Sep 30, 2025 | 4.41 Mn |
| Jun 30, 2025 | 5.49 Mn |
| Mar 31, 2025 | 7.70 Mn |
| Dec 31, 2024 | 9.81 Mn |
| Sep 30, 2024 | 254,000.00 |
| Jun 30, 2024 | 11.09 Mn |
| Mar 31, 2024 | 5.23 Mn |
| Dec 31, 2023 | 7.51 Mn |
| Sep 30, 2023 | 5.71 Mn |
| Jun 30, 2023 | 5.61 Mn |
| Mar 31, 2023 | 3.80 Mn |
| Dec 31, 2022 | 8.53 Mn |
| Sep 30, 2022 | 3.14 Mn |
| Jun 30, 2022 | 6.10 Mn |
| Mar 31, 2022 | 3.12 Mn |
| Dec 31, 2021 | 1.44 Mn |
| Sep 30, 2021 | 2.85 Mn |